We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

137 hedge funds and large institutions have $1.66B invested in Acceleron Pharma in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 49 increasing their positions, 41 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 41

13% more capital invested

Capital invested by funds: $1.47B → $1.66B (+$189M)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

8% less funds holding

Funds holding: 149 → 137 (-12)

17% less call options, than puts

Call options by funds: $4.12M | Put options by funds: $4.95M

39% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 28

Holders
137
Holders Change
-12
Holders Change %
-8.05%
% of All Funds
3.11%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.14%
New
17
Increased
49
Reduced
41
Closed
28
Calls
$4.12M
Puts
$4.95M
Net Calls
-$837K
Net Calls Change
+$8.23M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$51.7M
2
BlackRock
BlackRock
New York
+$16.3M
3
TCM
Tekla Capital Management
Massachusetts
+$8.39M
4
State Street
State Street
Massachusetts
+$8.27M
5
American Century Companies
American Century Companies
Missouri
+$6.8M

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$30.3M
2
Deutsche Bank
Deutsche Bank
Germany
-$14.7M
3
Millennium Management
Millennium Management
New York
-$13.4M
4
MWNA
Marshall Wace North America
New York
-$5.91M
5
IBT
International Biotechnology Trust
United Kingdom
-$5.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Artisan Partners
26
Artisan Partners
Wisconsin
$15.8M +$1.97M +52,567 +16%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$14.9M +$1.04M +27,598 +9%
First Manhattan
28
First Manhattan
New York
$13.6M -$225K -6,000 -2%
TCM
29
Tekla Capital Management
Massachusetts
$12M +$8.39M +223,729 +375%
FCMI
30
Foresite Capital Management III
California
$11.8M – – –
Axa
31
Axa
France
$11.4M -$10.4K -277 -0.1%
FCMI
32
Foresite Capital Management II
California
$10.4M – – –
GIM
33
Granahan Investment Management
Massachusetts
$9.6M +$343K +9,140 +4%
American Century Companies
34
American Century Companies
Missouri
$9.06M +$6.8M +181,423 +568%
GTC
35
Ghost Tree Capital
New York
$8.49M -$5.63M -150,000 -43%
Hudson Bay Capital Management
36
Hudson Bay Capital Management
Connecticut
$7.64M -$1.22M -32,500 -15%
Charles Schwab
37
Charles Schwab
California
$7.45M +$660K +17,601 +11%
GPP
38
Great Point Partners
Connecticut
$7.35M +$117K +3,124 +2%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$7M -$25.7K -686 -0.4%
BBA
40
Baker Bros. Advisors
New York
$6.96M – – –
Prudential Financial
41
Prudential Financial
New Jersey
$6.92M +$2.97M +79,100 +98%
UBS Group
42
UBS Group
Switzerland
$6.71M -$98.6K -2,629 -2%
Principal Financial Group
43
Principal Financial Group
Iowa
$5.84M +$1.22M +32,507 +31%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$5.13M +$432K +11,521 +11%
Morgan Stanley
45
Morgan Stanley
New York
$4.53M +$1.07M +28,594 +37%
OM
46
Opaleye Management
Massachusetts
$4.31M – – –
USAA
47
United Services Automobile Association
Texas
$4.05M +$146K +3,900 +4%
JP Morgan Chase
48
JP Morgan Chase
New York
$4.04M +$127K +3,399 +4%
TCIM
49
TIAA CREF Investment Management
New York
$3.69M +$119K +3,178 +4%
Citadel Advisors
50
Citadel Advisors
Florida
$3.6M -$5.73M -152,693 -64%
1
2
3 4 5

XLRN Hedge Fund Activity: Q4 2017 in Review

137 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2017, worth a combined $1.66B — up 13% from $1.47B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of XLRN and 17 opened new positions — a net loss of 11 holders — while 41 trimmed existing stakes and 49 added.

The largest buyer was Fidelity Investments, adding an estimated $51.7M. The largest seller was Citigroup, cutting an estimated $30.3M.

  • 137 institutional investors held Acceleron Pharma (XLRN) as of Q4 2017, down from 149 in Q3 2017.
  • Funds reported $1.66B of Acceleron Pharma stock for Q4 2017, up 13% quarter-over-quarter.
  • 17 funds opened new Acceleron Pharma positions in Q4 2017 and 28 closed out, a net change of -11 holders.
  • The largest Acceleron Pharma buyer in Q4 2017 was Fidelity Investments, an estimated $51.7M added.
  • The largest Acceleron Pharma seller in Q4 2017 was Citigroup, an estimated $30.3M sold.

Based on aggregated 13F filings for Q4 2017.